AGM
GNCA

Alpine Global Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Alpine Global Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,646
Closed -$120K – 204
2016
Q2 		$120K Buy
+3,646
New +$134K 0.05% 119

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Alpine Global Management's GNCA Position: Q3 2016 in Review

Alpine Global Management sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2016, closing a stake of 3,646 shares — an estimated $120K sold.

Alpine Global Management first reported a position in GNCA in Q2 2016 and held it in 1 quarter. The position peaked at $120K in Q2 2016. 48 funds tracked by Wall St. Rank hold GNCA as of Q3 2016.

  • Alpine Global Management reported no remaining Genocea Biosciences, Inc. position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 3,646 Genocea Biosciences, Inc. shares in Q3 2016, an estimated $120K.
  • Alpine Global Management first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 1 quarter.
  • Alpine Global Management's Genocea Biosciences, Inc. position peaked at $120K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.